IL-1β and TNF-? as a biomarker of recurrence in malignant eyelid tumors

---

Original Article

Author Details : Khalida Sayeed, Apjit Kaur, SK Bhasker, AB Pant

Volume : 2, Issue : 3, Year : 2016

Article Page : 164-167

Suggest article by email

Get Permission

---

Abstract

Aim: To establish a correlation between cytokine levels (IL-1β, TNF-? and IL-10) and establishing them as a biomarker of recurrence in malignant eyelid tumors.
Materials and Methods: Prospective observational cross-sectional case-control study of 38 consecutive cases of malignant eyelid tumors that underwent surgical treatment over a period of 18 months. 26 age and sex matched controls with other non-inflammatory, non- neoplastic eyelid disorders. The levels of the cytokines [IL-1β (Interleukin- 1β), TNF-? (Tumor necrosis factor-?), IL-10 (Interleukin-10)] (in pg/ml) were determined by using ELISA Kit. Data was analyzed statistically.
Result: On comparing the mean cytokine levels of the two groups, t-test revealed significantly higher levels of IL- 1β (16.39±2.86 vs. 14.62±3.72, t=2.17, p=0.034), TNF-? (19.32±3.47 vs. 16.74±4.45, t=2.61, p=0.011) and IL-10 (24.79±5.87 vs. 21.61 ± 4.61, t=2.33, p=0.023) in cases. ANOVA revealed significantly different levels of IL- 1β (F=7.86, p<0.001), TNF-? (F=7.42, p<0.001) and IL-10 (F=4.36, p=0.006) between tumor and it’s three adjacent tissues.
Conclusion: Cytokine levels (IL-1β, TNF-? and IL-10) in the adjacent tissues beyond safety margins were normal and comparable to that in controls suggesting the margins to be tumor free. Highly significant lower levels of IL-1β and TNF-? in tissues beyond safety margins can be used as an important predictor for local recurrence of tumor.

Keywords: IL-1β, Malignant eyelid tumor, Recurrence, TNF-?

 

How to cite : Sayeed K, Kaur A, Bhasker S, Pant A, IL-1β and TNF-? as a biomarker of recurrence in malignant eyelid tumors. IP Int J Ocul Oncol Oculoplasty 2016;2(3):164-167

This is an Open Access (OA) journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.